Patents by Inventor Bob Johan Scholte

Bob Johan Scholte has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220017572
    Abstract: Disclosed are geminoid peptide-like compound according to Formula I: R1—C(?O)—Zn—NR3-R2??(I) in which R1 and R2 are each independently saturated, partly saturated or unsaturated, straight, branched or cyclic alkyl chains, wherein R1 has a number of C atoms of 11 or more, preferably 11 to 19, and R2 has a number of C atoms of 12 or more, preferably 12 to 20; R3 is hydrogen or C1-C6 alkyl; n is an integer from 1-15; each Z independently is an amino acid residue, wherein Zn comprises an N-terminus attached to C(?O) and a C-terminus that is attached to NR3, for use as a medicament.
    Type: Application
    Filed: July 13, 2021
    Publication date: January 20, 2022
    Inventors: Bob Johan SCHOLTE, Martinus Christiaan FEITERS, Mark DAMEN
  • Publication number: 20190255141
    Abstract: Disclosed are geminoid peptide-like compound according to Formula (I): R1—C(=0)-Zn—NR3—R2 in which R1 and R2 are each independently saturated, partly saturated or unsaturated, straight, branched or cyclic alkyl chains, wherein R1 has a number of C atoms of 11 or more, preferably 11 to 19, and R2 has a number of C atoms of 12 or more, preferably 12 to 20; R3 is hydrogen or C1-C-6 alkyl; n is an integer from 1-15; each Z independently is an amino acid residue, wherein Zn comprises an N-terminus attached to C(=0) and a C-terminus that is attached to NR3, for use as a medicament.
    Type: Application
    Filed: June 16, 2017
    Publication date: August 22, 2019
    Inventors: Bob Johan SCHOLTE, Martinus Christiaan FEITERS, Mark DAMEN
  • Publication number: 20040019188
    Abstract: The present invention relates to a gene delivery vehicle comprising a general nucleic acid binding domain and an integrin binding domain. Typically, the at least two different domains of the gene delivery vehicle are somehow linked. The gene delivery vehicle may be used to deliver a therapeutic molecule to a cell exposing integrin to, at least in part, enhance the efficacy of gene delivery using integrin receptors. In one embodiment, the integrin binding domain is derived from the C-terminal region of the Yersinia pseudotuberculosis invasin or a functional homologue thereof.
    Type: Application
    Filed: February 3, 2003
    Publication date: January 29, 2004
    Inventor: Bob Johan Scholte